Abstract
Bone is the most common site for metastases in human prostate cancer patients. Skeletal metastases are a significant cause of morbidity and mortality and overall greatly affect the quality of life of patients. A significant portion of patients may be treated with curative intent when micrometastatic disease is present and not detected on current imaging studies, including bone scan and computed tomography scan. Molecular imaging approaches and, in particular Choline positron emission tomography, have been investigated to improve the detection of metastatic disease in patients with prostate cancer.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- 11C-CHO:
-
11C-choline
- 18F-CHO:
-
18F-choline
- ADT:
-
Androgen deprivation therapy
- BS:
-
Bone scintigraphy
- CRPC:
-
Castration-resistant prostate cancer
- CT:
-
Computed tomography
- 18F-FDG:
-
Fluorodeoxyglucose
- MRI:
-
Magnetic resonance imaging
- PET:
-
Positron emission tomography
- PSA:
-
Prostate-specific antigen
- RECIST:
-
Response Evaluation Criteria in Solid Tumours
- RT:
-
Radiation therapy
- SBRT:
-
Stereotactic body RT
- SUV:
-
Standardised uptake value
References
Podo F (1999) Tumour phospholipid metabolism. NMR Biomed 12(7):413–439
Janardhan S, Srivani P, Sastry GN (2006) Choline kinase: an important target for cancer. Curr Med Chem 13(10):1169–1186
Hara T, Kosaka N, Kishi H (1998) PET imaging of prostate cancer using carbon-11-choline. J Nucl Med Off Publ Soc Nucl Med 39(6):990–995
Torizuka T et al (2003) Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET. J Nucl Med Off Publ Soc Nucl Med 44(7):1051–1056
Wondergem M et al (2013) A literature review of 18F-fluoride PET/CT and 18F-choline or 11C-choline PET/CT for detection of bone metastases in patients with prostate cancer. Nucl Med Commun 34(10):935–945
Picchio M et al (2012) [11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy. Eur J Nucl Med Mol Imaging 39(1):13–26
Messiou C, Cook G, deSouza NM (2009) Imaging metastatic bone disease from carcinoma of the prostate. Br J Cancer 101:1225–1232
Evangelista L et al (2013) Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis. Eur Urol 63(6):1040–1048
De Bari B et al (2014) Choline-PET in prostate cancer management: the point of view of the radiation oncologist. Crit Rev Oncol Hematol 91(3):234–247
Tuncel M et al (2008) [(11)C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer. Nucl Med Biol 35(6):689–695
Langsteger W et al (2012) Imaging of bone metastases in prostate cancer: an update. Q J Nucl Med Mol Imaging Off Publ Ital Assoc Nucl Med 56(5):447–458
von Eyben FE, Kairemo K (2014) Meta-analysis of (11)C-choline and (18)F-choline PET/CT for management of patients with prostate cancer. Nucl Med Commun 35(3):221–230
Fuccio C et al (2012) Role of 11C-choline PET/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy. Eur J Radiol 81(8):e893–e896
Beheshti M et al (2008) Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging 35(10):1766–1774
Beer AJ et al (2011) Radionuclide and hybrid imaging of recurrent prostate cancer. Lancet Oncol 12(2):181–191
Beheshti M et al (2010) The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol Imaging Biol MIB Off Publ Acad Mol Imaging 12(1):98–107
Ayala-Peacock DN et al (2013) A pilot 11C-choline PET/CT imaging study investigating the ability to detect occult metastatic osseous disease in newly diagnosed high-risk prostate adenocarcinoma. Pract Radiat Oncol 3(2 Suppl 1):S27
Kjolhede H et al (2012) Combined 18F-fluorocholine and 18F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer. BJU Int 110(10):1501–1506
Poulsen MH et al (2012) [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients. BJU Int 110(11):1666–1671
Fuccio C et al (2010) Role of 11C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy. Ann Nucl Med 24(6):485–492
Poulsen MH et al (2014) Spine metastases in prostate cancer: comparison of technetium-99m-MDP whole-body bone scintigraphy, [(18) F]choline positron emission tomography(PET)/computed tomography (CT) and [(18) F]NaF PET/CT. BJU Int 114(6):818–823
Even-Sapir E et al (2006) The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med Off Publ Soc Nucl Med 47(2):287–297
Brogsitter C, Zophel K, Kotzerke J (2013) 18F-Choline, (11)C-choline and (11)C-acetate PET/CT: comparative analysis for imaging prostate cancer patients. Eur J Nucl Med Mol Imaging 40(Suppl 1):18–27
Fanti S et al (2011) Re: Nicolas Mottet, Joaquim Bellmunt, Michel Bolla, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011;59:572–83. Eur Urol 60(5):e37–e38; author reply e39–41
Ceci F et al (2015) 11C-choline PET/CT identifies osteoblastic and osteolytic lesions in patients with metastatic prostate cancer. Clin Nucl Med 40(5):e265–e270
Zhu A, Lee D, Shim H (2011) Metabolic positron emission tomography imaging in cancer detection and therapy response. Semin Oncol 38(1):55–69
Pinkawa M, Eble MJ, Mottaghy FM (2011) PET and PET/CT in radiation treatment planning for prostate cancer. Expert Rev Anticancer Ther 11(7):1033–1039
Das SK, Ten Haken RK (2011) Functional and molecular image guidance in radiotherapy treatment planning optimization. Semin Radiat Oncol 21(2):111–118
Shi X et al (2014) PET/CT imaging-guided dose painting in radiation therapy. Cancer Lett 355(2):169–175
Kunkler IH et al (2014) Review of current best practice and priorities for research in radiation oncology for elderly patients with cancer: the International Society of Geriatric Oncology (SIOG) task force. Ann Oncol Off J Eur Soc Med Oncol/ESMO 25(11):2134–2146
Husarik DB et al (2008) Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 35(2):253–263
Soyka JD et al (2012) Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer. Eur J Nucl Med Mol Imaging 39(6):936–943
Schick U et al (2013) Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases. Acta Oncol 52(8):1622–1628
Decaestecker K et al (2014) Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial. BMC Cancer 14:671
Ost P et al (2015) Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol 67(5):852–863
Gandaglia G et al (2014) Impact of the site of metastases on survival in patients with metastatic prostate cancer. Eur Urol 68(2):325–334
Rigaud J et al (2002) Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy. J Urol 168(4 Pt 1):1423–1426
Sabbatini P et al (1999) Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol 17(3):948–957
Weinfurt KP et al (2004) The impact of skeletal-related events on preferences and health-related quality of life of patients with metastatic prostate cancer. J Urol 171(4):42
Serpa Neto A et al (2010) A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma. BMC Urol 10:9
Muacevic A et al (2013) Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancer. Urol Oncol 31(4):455–460
Giovacchini G et al (2008) [(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging 35(6):1065–1073
Fuccio C et al (2011) Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study. Eur J Nucl Med Mol Imaging 38(11):1985–1989
Berkovic P et al (2013) Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Clin Genitourin Cancer 11(1):27–32
Ahmed KA et al (2012) Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Front oOncol 2:215
Milano MT et al (2012) Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys 83(3):878–886
Costelloe CM et al (2010) Cancer response criteria and bone metastases: RECIST 1.1, MDA and PERCIST. J Cancer 1:80–92
Eisenhauer EA et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247
Hamaoka T et al (2004) Bone imaging in metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 22(14):2942–2953
Kwee SA et al (2009) (18)F-Choline PET/CT imaging of RECIST measurable lesions in hormone refractory prostate cancer. Ann Nucl Med 23(6):541–548
Balogova S et al (2014) Whole-body 18F-fluorocholine (FCH) PET/CT and MRI of the spine for monitoring patients with castration-resistant prostate cancer metastatic to bone: a pilot study. Clin Nucl Med 39(11):951–959
Lecouvet FE et al (2014) Monitoring the response of bone metastases to treatment with Magnetic Resonance Imaging and nuclear medicine techniques: a review and position statement by the European Organisation for Research and Treatment of Cancer imaging group. Eur J Cancer 50(15):2519–2531
De Giorgi U et al (2014) Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone. Oncotarg et 5(23):12448–12458
De Giorgi U et al (2010) 18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. J Nucl Med Off Publ Soc Nucl Med 51(8):1213–1218
Ell PJ (2006) The contribution of PET/CT to improved patient management. Br J Radiol 79(937):32–36
Juweid ME, Cheson BD (2006) Positron-emission tomography and assessment of cancer therapy. N Engl J Med 354(5):496–507
Wahl RL et al (2009) From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med Off Publ Soc Nucl Med 50(Suppl 1):122S–150S
Morisson C, Jeraj R, Liu G (2013) Imaging of castration-resistant prostrate cancer: development of imaging response biomarkers. Curr Opin Urol 23(3):230–236
Kwee SA et al (2014) Prognosis related to metastatic burden measured by (1)(8)F-fluorocholine PET/CT in castration-resistant prostate cancer. J Nucl Med Off Publ Soc Nucl Med 55(6):905–910
Oprea-Lager DE et al (2015) Repeatability of quantitative 18F-fluoromethylcholine PET/CT studies in prostate cancer. J Nucl Med Off Publ Soc Nucl Med 57(5):721–727
Scher HI et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol Off J Am Soc Clin Oncol 26(7):1148–1159
McCarthy M et al (2011) (1)(8)F-Fluoromethylcholine (FCH) PET imaging in patients with castration-resistant prostate cancer: prospective comparison with standard imaging. Eur J Nucl Med Mol Imaging 38(1):14–22
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Incerti, E., Mapelli, P., Picchio, M. (2017). Detection of Bone Metastases and Evaluation of Therapy Response in Prostate Cancer Patients by Radiolabelled Choline PET/CT. In: Bertoldo, F., Boccardo, F., Bombardieri, E., Evangelista, L., Valdagni, R. (eds) Bone Metastases from Prostate Cancer . Springer, Cham. https://doi.org/10.1007/978-3-319-42327-2_7
Download citation
DOI: https://doi.org/10.1007/978-3-319-42327-2_7
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-42326-5
Online ISBN: 978-3-319-42327-2
eBook Packages: MedicineMedicine (R0)